A study published by JAMA Aug. 13 found that a two-dose antibiotic treatment could be just as effective as traditional long-term IV therapy for treating serious Staphylococcus aureus bloodstream infections. Researchers studied 200 patients with severe staph infections and randomly assigned them to receive either standard IV antibiotics over four to six weeks or two doses of dalbavancin administered one week apart. They found that dalbavancin performed equally well in curing infections and had slightly fewer side effects. The antibiotic reduced the need for home health visits, lab monitoring and risks associated with peripherally inserted central catheter lines. 

Related News Articles

Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
Ochsner Health's Stephen Saenz, sepsis program manager, and Teresa Arrington, director of robust process improvement for quality and patient safety, reveal how…
Headline
The Centers for Disease Control and Prevention Dec. 18 announced that a patient in Louisiana was hospitalized with a severe case of H5N1 bird flu, the first…
Headline
The Centers for Disease Control and Prevention Nov. 6 released its annual progress report on health care-associated infections, which showed continued…
Headline
The Food and Drug Administration last week granted enforcement discretion for the use of conjunctival swabs by laboratories as part of human testing for H5N1…
Headline
The White House April 16 released a strategy to guide the federal government in protecting the nation from infectious disease threats by working with other…